ClinicalTrials.gg
CompletedNCT07444164Updated Mar 2, 2026

Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination.

A Phase 1 interventional study of A1: Ticagrelor / Acetylsalicylic acid in fixed dose combination capsule. (Laboratorios Silanes S.A. de C.V.) and A2: Ticagrelor (BRILINTA®, AstraZeneca S.A. de C.V.) A3: Acetylsalicylic Acid (ASPIRINA JUNIOR®, Bayer de México S.A. de C.V.) in Healthy, sponsored by Laboratorios Silanes S.A. de C.V.. Completed at 1 site in Mexico. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Laboratorios Silanes S.A. de C.V. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Jan 2025, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Study conducted to determine and compare the relative bioavailability of two solid oral formulations (reference versus test) of the non-fixed combination of Ticagrelor 90 mg (Brilinta by AstraZeneca S.A. de C.V.) + Acetylsalicylic Acid 100 mg (ASPIRINA JUNIOR by Bayer de México S.A. de C.V.) administered concomitantly versus the fixed-dose combination of Ticagrelor 90 mg / Acetylsalicylic Acid 100 mg manufactured by Laboratorios Silanes S.A. de C.V.

Read the detailed description

Prospective, longitudinal, open-label, single-dose per period, two treatments two periods, crossover, balanced, randomized study with a 7-day washout period in 20 plus 4 (24) healthy research subjects of both genders, under fasting conditions. In order to establish characterization of the pharmacokinetic parameters Cmax, Tmax, T1/2, Ke, (AUC 0-t) and the (AUC 0-\~) when administered as a single dose of the non-fixed combination of Ticagrelor 90 mg (Brilinta by AstraZeneca S.A. de C.V.) + Acetylsalicylic Acid 100 mg (ASPIRINA JUNIOR by Bayer de México S.A. de C.V.) as a reference formulation and the fixed-dose combination of Ticagrelor 90 mg/ Acetylsalicylic Acid 100 mg as the test formulation manufactured by Laboratorios Silanes S.A. de C.V.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Laboratorios Silanes S.A. de C.V. is the lead sponsor of 45 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who have given in writting
  • Subjects of both genders aged between 18 and 55 years, mexicans, with no background of or allergies to the drugs under study or related drugs.
  • Subjects with no background of using anticoagulants of any kind.
  • Subjects with no background of and/or C.
  • Vital signs within normal limits, according to international guidelines recorded during selection.
  • Electrocardiographic trace without evidence of conduction disorders, with RR, PR, QRS, and ranges and ST segment values within physiological limits.
  • between 18.0 - 27.0 (kg/m2).
  • Negative drug abuse test for both men and women.
  • Negative pregnancy test for women.
  • All women who agree to participate in the study and who use some form of barrier method such as male or female condoms, copper intrauterine devices (IUDs), or male or female sterilization.
  • No background of food allergies.
  • No background of medication use for 14 consecutive days or less than 9 half-lives of the last dose administered of the indicated medication prior to the start of the study.
  • Background of participation in clinical studies similar to this one within a period of 3 months prior to the study.
  • No presence of Hepatitis B surface antigens or antibodies against , , and VDRL core proteins.
  • No background of alcohol consumption during the study selection period.
  • No background of donating or losing 450 mL or more of blood within 60 days prior to the study.

Exclusion criteria

Exclusion Criteria:

  • Individuals with to ticagrelor, acetylsalicylic acid, or any of their components.
  • Subjects with background of use of anticoagulants.
  • Subjects with background of and/or C.
  • Vital signs outside normal limits, according to international guidelines recorded during selection.
  • showing evidence of conduction disturbances, with RR, PR, QRS, and and ST segment values within physiological limits.
  • below 18.0 (kg/m2) or above 27.0 (kg/m2).
  • During the medical history process, the subject indicated background of abuse and dependence on alcohol, psychoactive substances, and chronic use of medications.
  • Positive drug abuse test for both men and women.
  • Positive pregnancy test for women.
  • Background of food allergies.
  • Background of participation in clinical studies similar to the present study within a period of less than 3 months prior to the study.
  • Presence of Hepatitis B surface antigens or antibodies against , , and VDRL core proteins.
  • Health assessment other than healthy, determined by the results of questioning, physical examination, laboratory tests: blood count, blood chemistry to assess liver and kidney function, fasting lipids and glucose, general urine test, and serology for hepatitis B and C, VDRL, HIV, and electrocardiogram.
  • In a subordinate relationship with the company or researcher.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Group A: Ticagrelor / Acetylsalicylic Acid in fixed dose combination.

    Pharmaceutical form: capsule. Each capsule contains: * Ticagrelor 90 mg * Acetylsalicylic Acid 100 mg Administration way: oral.

    Drug: A2: Ticagrelor (BRILINTA®, AstraZeneca S.A. de C.V.) A3: Acetylsalicylic Acid (ASPIRINA JUNIOR®, Bayer de México S.A. de C.V.)

  • Active comparator
    Group B: Ticagrelor / Group C: Acetylsalicylic acid.

    Group B: Ticagrelor Pharmaceutical form: Tablet. Formula: Each tablet contains 90 mg of Ticagrelor. Dosage: 1 tablet of 90 mg. Administration way: Oral. Group C: Acetylsalicylic Acid. Pharmaceutical form: Tablet. Formula: Each tablet contains 100 mg of Acetylsalicylic acid. Dosage: 1 tablet of 100 mg. Administration way: Oral.

    Drug: A1: Ticagrelor / Acetylsalicylic acid in fixed dose combination capsule. (Laboratorios Silanes S.A. de C.V.)

Interventions

06

What researchers measure

Primary outcomes

  1. Determine Cmax.

    Evaluate the pharmacokinetics profile of the fixed dose Ticagrelor/Acetylsalicylic Acid employing the maximum observed concentration following the treatment (Cmax), obtained graphically, from the plasma concentration profile with respect to time.

    Time frame: Baseline, 0.16, 0.33, 0.50, 0.75, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 24.0 and 48.0 hours.

  2. Determine AUC 0-t.

    Evaluate the pharmacokinetics profile of the fixed dose Ticagrelor/Acetylsalicylic Acid employing the area under the curve from time zero to the last measurable concentration (AUC 0-t) using the linear trapezoidal method.

    Time frame: Baseline, 0.16, 0.33, 0.50, 0.75, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 24.0 and 48.0 hours.

  3. Determine AUC 0-inf.

    Evaluate the pharmacokinetics profile of the fixed dose Ticagrelor/Acetylsalicylic Acid employing the area under the curve from time zero to infinity calculated (AUC 0-inf).

    Time frame: Baseline, 0.16, 0.33, 0.50, 0.75, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 24.0 and 48.0 hours.

  4. Determine Tmax.

    Evaluate the pharmacokinetics profile of the fixed dose Ticagrelor/Acetylsalicylic Acid employing the time of the maximum measured concentration (tmax) obtained graphically from the plasma concentration profile with respect to time.

    Time frame: Baseline, 0.16, 0.33, 0.50, 0.75, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 24.0 and 48.0 hours.

  5. Determine Ke.

    Evaluate the pharmacokinetics profile of the fixed dose Ticagrelor/Acetylsalicylic Acid employing the elimination rate (Ke) estimated from the terminal linear portion of the plasma concentration profile with respect to time (on a semi-log scale).

    Time frame: Baseline, 0.16, 0.33, 0.50, 0.75, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 24.0 and 48.0 hours.

  6. Determine T1/2.

    Evaluate the pharmacokinetics profile of the fixed dose Ticagrelor/Acetylsalicylic Acid employing the half time elimination (t1/2) by the quotient of Ln(2) Ke.

    Time frame: Baseline, 0.16, 0.33, 0.50, 0.75, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 24.0 and 48.0 hours.

Secondary outcomes

  1. Determine the frequency of occurrence of adverse events

    The percentage of frequency of appearance of each adverse event was evaluated.

    Time frame: 1, 2, 9 and 11 days.

  2. Adverse events

    Any adverse event were classified by severity, treatment and its relationship with the study drug was evaluated.

    Time frame: 1, 2, 9 and 11 days.

07

Study locations

1 site
  • Centro de Estudios Científicos y Clínicos Pharma S.A. de C.V.
    Xochitepec, Morelos 627790, Mexico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Jan 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Mar 2, 2026
StartActual
Jan 13, 2025
Primary completionActual
Jan 23, 2025
CompletionActual
Feb 5, 2025
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07444164
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Jan 13, 2025
Primary completion
Jan 23, 2025
Completion
Feb 5, 2025
Last update
Mar 2, 2026

Study contacts

Susana Tera - Ponce, Dr.
principal investigator · Centro de Estudios Científicos y Clínicos Pharma S.A. de C.V.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion